Catia Cillóniz1, Antoni Torres2, Christian Manzardo3, Albert Gabarrús1, Juan Ambrosioni3, Adriana Salazar4, Felipe García3, Adrián Ceccato5, Josep Mensa3, Jorge Puig de la Bella Casa6, Asunción Moreno3, Jose M Miró3. 1. Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Ciber de Enfermedades Respiratorias (Ciberes) Barcelona, Spain. 2. Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Ciber de Enfermedades Respiratorias (Ciberes) Barcelona, Spain. Electronic address: atorres@clinic.ub.es. 3. Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. 4. Infectología de Adultos, Hospital General Regional nº1, Instituto Mexicano del Seguro Social, Tijuana, BC, Mexico. 5. Seccion Neumología, Hospital Nacional Alejandro Posadas, Palomar, Argentina. 6. Department of Microbiology, Hospital Clinic of Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: The study aimed to investigate whether the clinical presentations and outcomes (length of stay, ICU admission, and 30-day mortality) of pneumococcal pneumonia in virologically suppressed patients who were HIV-infected on ART with a CD4+ T-cell count > 350 cells/mm3 are comparable to those seen in patients with HIV, using a case-control design. METHODS: A case-control study was carried out in Hospital Clinic, Barcelona, Spain (2001-2016). Control patients were matched by age (±10 years), sex, comorbidities, and pneumonia diagnosis in the same calendar period. Clinical presentation and outcomes of pneumococcal pneumonia in patients who were and were not infected with HIV were compared. RESULTS: Pneumococcal pneumonia was studied in 50 cases (HIV infection) and 100 control patients (non-HIV infection). Compared with the control patients, case patients had higher rates of influenza (14% vs 2%, P = .007) and pneumococcal vaccination (10% vs 1%, P = .016). The group of cases also presented a higher rate of coinfection with hepatitis B virus (6% vs 0%, P = .036). Both groups presented similar ICU admission (18% vs 27%, P = .22), need for mechanical ventilation (12% vs 8%; P = .43), length of stay (7 days vs 7 days, P = .76), and 0% of 30-day mortality. No evidence was found of a more severe presentation or a worse clinical outcome in cases than in control patients. CONCLUSIONS: Pneumococcal pneumonia episodes requiring hospitalization in virologically suppressed patients with HIV with > 350 CD4+ T-cell count/mm3 were neither more severe nor had worse prognosis compared with uninfected patients. These results support the fact that such patients do not need treatment, admission, or care sites different to the general population. TRIAL REGISTRY: ClinicalTrials.gov; No. 2009/5451; URL: www.clinicaltrials.gov.
BACKGROUND: The study aimed to investigate whether the clinical presentations and outcomes (length of stay, ICU admission, and 30-day mortality) of pneumococcal pneumonia in virologically suppressed patients who were HIV-infected on ART with a CD4+ T-cell count > 350 cells/mm3 are comparable to those seen in patients with HIV, using a case-control design. METHODS: A case-control study was carried out in Hospital Clinic, Barcelona, Spain (2001-2016). Control patients were matched by age (±10 years), sex, comorbidities, and pneumonia diagnosis in the same calendar period. Clinical presentation and outcomes of pneumococcal pneumonia in patients who were and were not infected with HIV were compared. RESULTS:Pneumococcal pneumonia was studied in 50 cases (HIV infection) and 100 control patients (non-HIV infection). Compared with the control patients, case patients had higher rates of influenza (14% vs 2%, P = .007) and pneumococcal vaccination (10% vs 1%, P = .016). The group of cases also presented a higher rate of coinfection with hepatitis B virus (6% vs 0%, P = .036). Both groups presented similar ICU admission (18% vs 27%, P = .22), need for mechanical ventilation (12% vs 8%; P = .43), length of stay (7 days vs 7 days, P = .76), and 0% of 30-day mortality. No evidence was found of a more severe presentation or a worse clinical outcome in cases than in control patients. CONCLUSIONS:Pneumococcal pneumonia episodes requiring hospitalization in virologically suppressed patients with HIV with > 350 CD4+ T-cell count/mm3 were neither more severe nor had worse prognosis compared with uninfected patients. These results support the fact that such patients do not need treatment, admission, or care sites different to the general population. TRIAL REGISTRY: ClinicalTrials.gov; No. 2009/5451; URL: www.clinicaltrials.gov.
Authors: Derrick R Samuelson; Robert W Siggins; Sanbao Ruan; Angela M Amedee; Jiusong Sun; Quan Karen Zhu; Wayne A Marasco; Christopher M Taylor; Meng Luo; David A Welsh; Judd E Shellito Journal: Alcohol Date: 2018-09-11 Impact factor: 2.405
Authors: François Barbier; Mervin Mer; Piotr Szychowiak; Robert F Miller; Éric Mariotte; Lionel Galicier; Lila Bouadma; Pierre Tattevin; Élie Azoulay Journal: Intensive Care Med Date: 2020-02-03 Impact factor: 17.440
Authors: Jerry S Zifodya; Meredith S Duncan; Kaku A So-Armah; Engi F Attia; Kathleen M Akgün; Maria C Rodriguez-Barradas; Vincent C Marconi; Matthew J Budoff; Roger J Bedimo; Charles W Alcorn; Guy W Soo Hoo; Adeel A Butt; Joon W Kim; Jason J Sico; Hilary A Tindle; Laurence Huang; Janet P Tate; Amy C Justice; Matthew S Freiberg; Kristina Crothers Journal: J Am Heart Assoc Date: 2020-11-23 Impact factor: 5.501
Authors: Lessandra Michelin; Fernanda M Weber; Bruna W Scolari; Bruna K Menezes; Maria Carolina Gullo Journal: J Bras Pneumol Date: 2019-10-17 Impact factor: 2.624